Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment ...
Shaw said Biocon’s growth trajectory over the next five years will be “very exciting,” with even larger opportunities emerging beyond 2030 as big-ticket biologics go off patent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback